852854-29-6

Basic information

• Product Name: ethyl 5-aMino-1-cyclopropyl-1H-iMidazole-4-carboxylate
• Synonyms: ethyl 5-aMino-1-cyclopropyl-1H-iMidazole-4-carboxylate
• CAS NO: 852854-29-6
• Molecular Formula: C₉H₁₃N₃O₂
• Molecular Weight: 195.21842
• Mol File: 852854-29-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 5-aMino-1-cyclopropyl-1H-iMidazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-aMino-1-cyclopropyl-1H-iMidazole-4-carboxylate(852854-29-6)
• EPA Substance Registry System: ethyl 5-aMino-1-cyclopropyl-1H-iMidazole-4-carboxylate(852854-29-6)

Safety Data

• Hazardous Substances Data: 852854-29-6(Hazardous Substances Data)

Upstream product

• 3849-21-6 ethyl cyanoglyoxylate-2-oxime 
• 105-56-6 ethyl 2-cyanoacetate 
• 765-30-0 Cyclopropylamine 
• 122-51-0 orthoformic acid triethyl ester 
• 32683-02-6 ethyl-2-aminocyano acetate 

Downstream Products

• 914917-96-7 1-(4-chlorophenyl)-9-cyclopropyl-2-(methylsulfonyl)-1,9-dihydro-6H-purin-6-one 
• 914917-95-6 1-(4-chlorophenyl)-9-cyclopropyl-2-(methylthio)-1,9-dihydro-6H-purin-6-one 
• 852854-30-9 ethyl 5-(4-chlorophenylaminocarbonothioylamino)-1-cyclopropyl-1H-imidazole-4-carboxylate 

Relevant articles and documents

Synthesis and anticancer activity of ethyl 5-amino-1-N-substituted-imidazole-4-carboxylate building blocks

A series of 5-amino-1-N-substituted-imidazole-4-carboxylate building blocks was synthesized and assayed for their antiproliferative potential against human cancer cell lines, including HeLa (cervical), HT-29, HCT-15 (colon), A549 (lung), and MDA-MB-231 (breast) cells. The preliminary screening results revealed that several derivatives containing alkyl chains at the N-1 position of the imidazole core demonstrate a certain inhibitory effect on growth and proliferation. A significant effect was observed following ethyl 5-amino-1-dodecyl-1H-imidazole-4-carboxylate (5e) treatment for 72 h. The IC50 value for HeLa cells was 0.737 ± 0.05 μM, whereas that for HT-29 cells was 1.194 ± 0.02 μM. Further investigations revealed that 5e significantly inhibited tumor cell colony formation and migration, and it exhibited antiadhesive effects on HeLa cells as well as antitubulin activity along with the induction of early apoptosis of HeLa and HT-29 cells. In addition, derivative 5e significantly reduced the cell mitochondrial membrane potential in a dose-dependent manner and induced early apoptosis of HeLa and HT-29 cells, indicating that 5e may serve as a lead compound for further drug discovery and development.

SUBSTITUTED ARYL PYRIMIDINONE DERIVATIVES

Substituted aryl pyrimidinone derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES

Cis-cyclohexyl substituted pyrimidinone derivatives are provided, of Formula (I) wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful